◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Siegfried Holding AG (SFZN) Financial History

Name: Siegfried Holding AG (SFZN) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-16

Siegfried Holding AG (SFZN) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Zofingen, Switzerland with about 3,891 employees. Its market capitalization is roughly CHF 3 billion. In the fiscal year ended 2025-12-31, SFZN reported CHF 1.3B in revenue and CHF 169M in net income.

Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs.

Interactive charts & full statements →

SFZN Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Revenue	CHF 1.3B	CHF 1.3B	CHF 1.3B	CHF 1.2B	—
Gross Profit	CHF 354M	CHF 329M	CHF 320M	CHF 319M	—
Operating Income (EBIT)	CHF 216M	CHF 195M	CHF 169M	CHF 229M	—
Net Income	CHF 169M	CHF 160M	CHF 113M	CHF 156M	—

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SFZN Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Dividends Paid	(CHF 17M)	(CHF 15M)	(CHF 14M)	(CHF 14M)	—

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SFZN Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	CHF 2.2B	CHF 1.9B	CHF 1.9B	CHF 1.8B	—
Total Liabilities	CHF 1.0B	CHF 954M	CHF 1.0B	CHF 1.0B	—

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SFZN viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

3613 · Beijing Tong Ren Tang Chinese Medicine Company Limited — $6 billion
INDV · Indivior Pharmaceuticals, Inc. — $5 billion
0719 · Shandong Xinhua Pharmaceutical Company Limited — $4 billion
CURA · Curaleaf Holdings, Inc. — $3 billion
HIK · Hikma Pharmaceuticals PLC — $3 billion
SUPN · Supernus Pharmaceuticals, Inc. — $3 billion
1349 · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. — $3 billion
AMLX · Amylyx Pharmaceuticals, Inc. — $3 billion

← SFWL All “S” companies SG →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.